- Home
- / 4D Molecular Therapeutics
4D Molecular Therapeutics4D Molecular Therapeutics
IND-Enabling Stage Products
3
Q3, 2020
Revenue
$18 M
FY, 2021
Market Capitalization
$637.6 M
2023-01-23
4D Molecular Therapeutics Summary
Company summary
- Overview
- 4D Molecular Therapeutics is a biotechnology company focused on the creation of gene therapy products to cure genetic diseases. Its Therapeutic Vector Evolution platform enables to create adeno-associated virus (AAV) gene therapy vectors, which deliver genes to any diseased tissue or organ in the body.
- Type
- Public
- Status
- Active
- Founded
- 2013
- HQ
- Emeryville, CA, US | view all locations
- Cybersecurity rating
- ESG rating
Key people
August Moretti, Chief Financial Officer
Melissa Kotterman, Vice President, Head of Discovery & Engineering, Co-Founder
Katy Barglow, Vice President, Process and Analytical Development
Operating MetricsView all
Lead Optimization Stage Products
3
Q2, 2019
IND-Enabling Stage Products
3
Q3, 2020
Phase I Trials Products
3
Q3, 2020
4D Molecular Therapeutics Financials
Summary financials
- Revenue (Q3, 2022)
- $500.0K
- Net income (Q3, 2022)
- ($25.7M)
- EBIT (Q3, 2022)
- ($26.5M)
